Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Onychomycosis Treatment Market Through 2034?

In recent times, there has been a marked increase in the size of the market for onychomycosis treatment. The market, which was worth $3.65 billion in 2024, is projected to expand to $3.91 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.1%. The notable growth in the previous period could be ascribed to factors such as the surge in fungal infections, an aging population, enhanced public awareness, a heightened incidence of onychomycosis, and ascending disposable incomes.

Anticipated robust expansion is on the horizon for the onychomycosis treatment market, with a projected growth to$5.1 billion by 2029, boasting a compound annual growth rate (CAGR) of 6.9%. This predicted growth during the forecast period can be credited to various factors such as the increasing elderly population, the broadening of telemedicine, the advent of combination therapies, improved access to healthcare, evolving lifestyles, and environmental factors, as well as the rising incidence of diabetes. Notable trends to look out for within this forecast period include advancements in dermatology, innovative drug delivery techniques, the rise of personalized treatment regimens, progress in topical treatment methods, the uprising of digital health solutions and the development of laser therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

Which Primay Drivers Are Accelerating Growth in the Onychomycosis Treatment Market?

The rise in fungal infections is predicted to provide impetus for the expansion of the onychomycosis treatment market. These infections, caused by different types of fungi, impact various parts of the body and lead to specific conditions. One such condition, Onychomycosis, a fungal nail infection, is usually addressed with oral antifungal drugs or local antifungal solutions to eradicate the underlying fungal proliferation and promote the growth of a healthy nail. As an example, in September 2023, the UK Health Security Agency, a governmental agency in the UK, registered 2,265 cases of bloodstream infections (BSI) due to yeast in England in 2022, as tracked by the SGSS. The overall prevalence rate of BSI due to yeast saw a slight rise to 4.0 per 100,000 population, an increase from 3.8 per 100,000 in 2021. The three yeast species most commonly found in blood samples included Candida albicans (40%), Nakaseomyces glabratus (formerly known as Candida glabrata, 29%), and Candida parapsilosis (13%). Hence, the surge in fungal infections is a key driver for the onychomycosis treatment market’s growth.

Which Primary Segments of the Onychomycosis Treatment Market Are Driving Growth and Industry Transformations?

The onychomycosis treatmentmarket covered in this report is segmented –

1) By Type: Distal Sublingual Onychomycosis; White Superficial Onychomycosis; Proximal Sublingual Onychomycosis; Candida Onychomycosis; Other Types

2) By Treatment Type: Drugs; Laser Therapy; Photodynamic Therapy

3) By Age Group: 0 To 18 Years; 18 To 39 Years; 40 To 64 Years; 65 Years And Above

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Onychomycosis Treatment Market?# Market?

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Onychomycosis Treatment Industry Dynamics?

Leading companies in the onychomycosis treatment market are striving to maintain their competitive edge by producing innovative new products such as MOB-015 and seeking their approval from government agencies. For example, in June 2023, Moberg Pharma AB, a pharmaceutical company based in Sweden, secured approval for MOB-015 from the European Union. This approval signified the inaugural global marketing authorization for the pioneering onychomycosis medication. MOB-015’s approval was backed by results from two Phase 3 tests that exhibited enhanced mycological cure (76% compared to up to 42% for competitors) and a significantly higher total cure rate than the vehicle, without manifesting any serious side effects. The MOB-015 topical terbinafine formulation allows effective terbinafine concentrations to permeate the nail and nail bed, circumventing the risk of systemic exposure linked with oral terbinafine treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

What Parameters Are Used to Define the Onychomycosis Treatment Market?

Onychomycosis treatment refers to the medical interventions and approaches used to manage and cure onychomycosis, a fungal infection that affects the nails, including both the fingernails and toenails. Treating onychomycosis typically involves a combination of topical and oral antifungal medications and preventive measures to reduce the risk of recurrence.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model